4.8 Article

ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia

Journal

NATURE COMMUNICATIONS
Volume 8, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms15429

Keywords

-

Funding

  1. Fondation de France
  2. Philippe Foundation
  3. Japan Society for the Promotion of Science
  4. YASUDA Medical Foundation
  5. Kanae Foundation for the Promotion of Medical Science
  6. Worldwide Cancer Research Fund
  7. Leukemia and Lymphoma Society (LLS) Special Fellow Award
  8. American Society of Hematology (ASH)
  9. Aplastic Anemia and MDS Research Foundation
  10. Edward P. Evans Foundation
  11. Dept. of Defense Bone Marrow Failure Research Program [BM150092, W81XWH-12-1-0041]
  12. NIH/NHLBI [R01 HL128239]
  13. NIH K08 Clinical Investigator Award [1K08CA160647-01]
  14. Josie Robertson Investigator Program
  15. Damon Runyon Clinical Investigator Award
  16. Starr Foundation [I8-A8-075]
  17. Leukemia and Lymphoma Society
  18. Pershing Square Sohn Cancer Research Alliance

Ask authors/readers for more resources

Additional sex combs-like (ASXL) proteins are mammalian homologues of additional sex combs (Asx), a regulator of trithorax and polycomb function in Drosophila. While there has been great interest in ASXL1 due to its frequent mutation in leukemia, little is known about its paralog ASXL2, which is frequently mutated in acute myeloid leukemia patients bearing the RUNX1-RUNX1T1 (AML1-ETO) fusion. Here we report that ASXL2 is required for normal haematopoiesis with distinct, non-overlapping effects from ASXL1 and acts as a haploinsufficient tumour suppressor. While Asxl2 was required for normal haematopoietic stem cell self-renewal, Asxl2 loss promoted AML1-ETO leukemogenesis. Moreover, ASXL2 target genes strongly overlapped with those of RUNX1 and AML1-ETO and ASXL2 loss was associated with increased chromatin accessibility at putative enhancers of key leukemogenic loci. These data reveal that Asxl2 is a critical regulator of haematopoiesis and mediates transcriptional effects that promote leukemogenesis driven by AML1-ETO.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available